Sanofi Follows Lilly, Novo Nordisk in Cutting Insulin Prices
Sanofi is the third company to cut prices on its insulin products and cap out-of-pocket charges to $35 a month
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.